TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage company developing novel therapies for treatment of the most aggressive cancers, announced on Monday that it showcased updated results from the NOX-A12 GLORIA Phase 1/2 trial at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona.
Led by Dr Frank A. Giordano, the trial examined the efficacy of combining NOX-A12 with bevacizumab in treating newly diagnosed glioblastoma patients resistant to standard chemotherapy.
The data highlighted a significant improvement in survival rates for patients receiving the NOX-A12 and bevacizumab combination. Compared to standard of care or NOX-A12 alone, the combination therapy resulted in longer median progression-free survival (9.1 months vs. 4.0 months and 5.7 months) and median overall survival (19.9 months vs. 9.5 months and 12.7 months). Additionally, the combination led to a notable decrease in tumor blood flow, reinforcing its mechanism of action.
Titled 'Dual inhibition of postradiogenic angio-vasculogenesis in glioblastoma: Results of the phase 1/2 GLORIA trial', the presentation took place during the mini oral session on CNS tumors. The trial's findings include that two out of six patients in the NOX-A12 and bevacizumab arm survived beyond 26 months.
TME Pharma is advancing the NOX-A12 programme, with ongoing trials evaluating its combination with radiotherapy and other agents. The FDA has approved a randomized Phase 2 trial design and granted fast track designation to NOX-A12. TME Pharma is also exploring the potential of NOX-A12 in metastatic pancreatic cancer through its OPTIMUS study.
NCI reports IND submission for pilot study of Senhwa Biosciences Inc's developed Pidnarulex
Epitomee Medical's Capsule cleared by FDA for weight management
TME Pharma presents promising NOX-A12 trial results at ESMO Congress 2024
Roche's OCREVUS ZUNOVO with Halozyme's ENHANZE drug delivery technology receives FDA approval
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Neuspera Medical names new chief operating officer
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Dupixent shows promise in treating chronic spontaneous urticaria
Aisa Pharma receives orphan drug designation from FDA for AISA-021(cilnidipine)
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024